«Bristol - Myers Squibb is thrilled to be part of an innovative research model where each partner acts with urgency to advance potential new treatments for patients
facing deadly cancers,» said Awny Farajallah, M.D., vice president, head of U.S. Medical Oncology at Bristol - Myers Squibb.
Genetically modified «hunter» T cells successfully migrated to and penetrated a
deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and
faced a complex mutational landscape that will need to be overcome to better treat this aggressive
cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.